Skip to content

Alemtuzumab

Campath, Lemtrada (alemtuzumab) is an antibody pharmaceutical. Alemtuzumab was first approved as Campath on 2001-05-07. It is used to treat b-cell chronic lymphocytic leukemia in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against CAMPATH-1 antigen.
Trade Name Lemtrada
Common Name Alemtuzumab
Indication b-cell chronic lymphocytic leukemia, multiple sclerosis
Drug Class Monoclonal antibodies: humanized, tumors as target
Alemtuzumab
Get full access now